Investigational drugs chosen for major Alzheimer's prevention trial

October 10, 2012

Leading scientists have selected the first drugs to be evaluated in a worldwide clinical study to determine whether they can prevent Alzheimer's disease.

The pioneering trial, expected to start by early 2013, initially will test three , each designed to target Alzheimer's in different ways.

In people with inherited that cause early-onset Alzheimer's, the study will seek to identify whether the drugs can improve Alzheimer's disease and effectively prevent the loss of cognitive function.

"This trial is the result of a groundbreaking collaboration between academic institutions, pharmaceutical companies and patient advocacy groups, with key support from regulatory groups," says principal investigator Randall Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor in Neurology at Washington University School of Medicine in St. Louis. "We are excited that this diverse portfolio of drugs and approaches will accelerate the discovery of an effective treatment for Alzheimer's."

The trial will be conducted by the Dominantly Inherited Alzheimer's Network Trials Unit (DIAN TU) at Washington University School of Medicine in St. Louis. The trials unit is supported by the DIAN, an NIH-funded collaboration of world-leading Alzheimer's research centers; the Alzheimer's Association; and the DIAN Pharma Consortium, composed of 10 that have been advising DIAN researchers on the planning of the trial.

Alzheimer's researchers have selected the investigational drugs from more than a dozen nominations submitted by the DIAN Pharma Consortium. Each drug has a unique approach to counter the of amyloid beta, the main ingredient of found in Alzheimer's patients. Each also has passed earlier that evaluated safety and effectiveness of the drugs and whether they engaged their targets in patients.

The investigational drugs are:

*Gantenerumab, an antibody made by Roche that binds to all forms of aggregated amyloid beta and helps remove them from the brain. Gantenerumab is currently in an international phase II/III trial known as SCarlet RoAD, started in 2010, that will test the drug's ability to stop Alzheimer's prior to dementia.

*Solanezumab, a monoclonal antibody in phase III clinical trials. Discovered and developed by Eli Lilly and Company, it binds to soluble forms of amyloid beta after they are produced, allowing amyloid beta to be cleared before it clumps together to form plaques.

Also selected for potential inclusion in the trial is a beta-secretase (BACE) inhibitor, a small molecule in Phase II clinical trials that was also discovered and developed by Lilly. BACE is theorized to work by reducing the amount of amyloid beta proteins produced, slowing the accumulation of plaques.

Roche and Lilly have agreed to make the treatments available at no cost to the investigators. The two companies also will provide supporting grants for each drug to help make the trial possible. The new trial also is supported by a $4.2 million grant from the Alzheimer's Association. The researchers have applied for support through the National Institutes of Health; the National Institute on Aging is currently reviewing the grant application.

"Trying to prevent Alzheimer's symptoms from ever occurring is a new strategy," says John C. Morris, MD, principal investigator of DIAN and the Harvey A. and Doris Friedman Distinguished Professor of Neurology at the School of Medicine. "We are most appreciative of the support this approach has received."

The trial will involve 160 people who have inherited mutations that mean they are almost certain to develop Alzheimer's at a young age, typically in their 30s, 40s or 50s. The trial also will monitor the health of 80 DIAN participants who did not inherit the Alzheimer's mutations.

"This is a very exciting moment in Alzheimer's disease research, and it gives me renewed hope for a future without Alzheimer's," says DIAN participant Brent Whitney. "I hope my grandchildren someday learn of this condition in history books, like I learned about polio."

Participants with inherited forms of Alzheimer's will be randomly assigned to receive one of three investigational drugs (75 percent chance) or a placebo (25 percent chance). Those without mutations also will receive a placebo.

"Normally in clinical trials there is a 50/50 chance of receiving the active or a placebo, but the efficient design of testing three drugs will allow us to significantly boost the number of participants who receive active treatments," Bateman says.

All of the experimental group's subjects will be within 10 to 15 years of the anticipated age when symptoms of cognitive decline and dementia are expected to appear. Earlier DIAN studies have shown that at this point in their lives, people who have Alzheimer's mutations are likely to have biological indicators that show the disease is beginning in the brain, including evidence of brain plaques and changes in the blood and cerebrospinal fluid.

Scientists will monitor these indicators of early Alzheimer's to see whether the new treatments slow or stop the disease process. The first part of the trial is planned to last for two years. It will be expanded and extended if one or more of the drugs are effective in slowing or stopping indicators of presymptomatic Alzheimer's disease.

"Roche is honored that gantenerumab was selected by DIAN to be a part of this groundbreaking Alzheimer's disease study," says Luca Santarelli, head of Roche Neurosciences. "This clinical test supports Roche's commitment to provide earlier treatment options to those at risk for this devastating disease."

"We are pleased that Lilly was chosen to contribute solanezumab, and potentially our beta-secretase inhibitor, for use in this pioneering Alzheimer's disease study," said Jan Lundberg, PhD, executive vice president, science and technology, and president, Lilly Research Laboratories. "We look forward to collaborating with the DIAN TU investigators, along with the other public and private partners, to better understand if early treatment with these investigational medicines can influence this terrible disease."

Explore further: Inherited Alzheimer's detectable 20 years before dementia

More information: www.dianxr.org/

Related Stories

Inherited Alzheimer's detectable 20 years before dementia

July 20, 2011
Inherited forms of Alzheimer's disease may be detectable as many as 20 years before problems with memory and thinking develop, scientists will report July 20, 2011, at the Alzheimer's Association International Conference ...

First detailed timeline established for brain's descent into Alzheimer's

July 11, 2012
Scientists have assembled the most detailed chronology to date of the human brain's long, slow slide into full-blown Alzheimer's disease.

Novel approaches to treating Alzheimer's disease include early intervention

May 16, 2012
(Medical Xpress) -- Researchers at the Comprehensive Alzheimer’s Program at the University of California, San Diego School of Medicine have announced two new clinical trials for patients with either mild to moderate ...

Trial set to see if drug can prevent Alzheimer's

May 16, 2012
(HealthDay) -- Researchers are preparing to test an experimental drug in people genetically primed to develop Alzheimer's disease.

Road block as a new strategy for the treatment of Alzheimer's

August 22, 2011
Blocking a transport pathway through the brain cells offers new prospects to prevent the development of Alzheimer's. Wim Annaert and colleagues of VIB and K.U. Leuven discovered that two main agents involved in the inception ...

Alzheimer’s prevention better than a cure

July 14, 2011
In a new study published in Nature, Dr. Sam Gandy from Mount Sinai Medical Center argues that finding a cure for Alzheimer’s disease may be near impossible and that the best hope for researchers is to focus on prevention, ...

Recommended for you

Noninvasive eye scan could detect key signs of Alzheimer's years before patients show symptoms

August 17, 2017
Cedars-Sinai neuroscience investigators have found that Alzheimer's disease affects the retina—the back of the eye—similarly to the way it affects the brain. The study also revealed that an investigational, noninvasive ...

Could olfactory loss point to Alzheimer's disease?

August 16, 2017
By the time you start losing your memory, it's almost too late. That's because the damage to your brain associated with Alzheimer's disease (AD) may already have been going on for as long as twenty years. Which is why there ...

New Machine Learning program shows promise for early Alzheimer's diagnosis

August 15, 2017
A new machine learning program developed by researchers at Case Western Reserve University appears to outperform other methods for diagnosing Alzheimer's disease before symptoms begin to interfere with every day living, initial ...

Brain scan study adds to evidence that lower brain serotonin levels are linked to dementia

August 14, 2017
In a study looking at brain scans of people with mild loss of thought and memory ability, Johns Hopkins researchers report evidence of lower levels of the serotonin transporter—a natural brain chemical that regulates mood, ...

Alzheimer's risk linked to energy shortage in brain's immune cells

August 14, 2017
People with specific mutations in the gene TREM2 are three times more likely to develop Alzheimer's disease than those who carry more common variants of the gene. But until now, scientists had no explanation for the link.

Scientists reveal role for lysosome transport in Alzheimer's disease progression

August 7, 2017
Researchers from Yale University School of Medicine have discovered that defects in the transport of lysosomes within neurons promote the buildup of protein aggregates in the brains of mice with Alzheimer's disease. The study, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.